placebo + ADT

Placebo + ADT refers to a control treatment arm used in clinical trials, specifically those conducted by Otsuka Pharmaceutical for Major Depressive Disorder (MDD). In this regimen, patients receive an inactive placebo alongside an open-label, marketed antidepressant therapy (ADT) to which they previously showed an incomplete response. The ADT typically consists of standard-of-care agents such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). This combination serves as a comparator to evaluate the efficacy and safety of adjunctive treatments, such as aripiprazole or brexpiprazole, when added to existing antidepressant therapy. The placebo component contains no active pharmacological ingredient, while the ADT component provides the baseline therapeutic effect against which the investigational drug's adjunctive benefit is measured.

Other names

placebo plus antidepressant therapyplacebo + antidepressant therapy